List of Tables
    Table 1. Human Immumoglobulin (PH4) for Intravenous Injection CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. Human Immumoglobulin (PH4) for Intravenous Injection Market Trends
    Table 3. Human Immumoglobulin (PH4) for Intravenous Injection Market Drivers
    Table 4. Human Immumoglobulin (PH4) for Intravenous Injection Market Challenges
    Table 5. Human Immumoglobulin (PH4) for Intravenous Injection Market Restraints
    Table 6. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Human Immumoglobulin (PH4) for Intravenous Injection Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Share by Manufacturer, 2017-2022
    Table 13. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Manufacturer, (K Units), 2017-2022
    Table 14. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Share by Manufacturer, 2017-2022
    Table 15. Global Human Immumoglobulin (PH4) for Intravenous Injection Price by Manufacturer (2017-2022) & (US$/Unit)
    Table 16. Global Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global Human Immumoglobulin (PH4) for Intravenous Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Immumoglobulin (PH4) for Intravenous Injection as of 2021)
    Table 18. Top Players of Human Immumoglobulin (PH4) for Intravenous Injection in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Product Type
    Table 20. Date of International Manufacturers Enter into Human Immumoglobulin (PH4) for Intravenous Injection Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top Human Immumoglobulin (PH4) for Intravenous Injection Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States Human Immumoglobulin (PH4) for Intravenous Injection Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States Human Immumoglobulin (PH4) for Intravenous Injection Sales by Players, (K Units), 2020, 2021 & 2022
    Table 26. United States Human Immumoglobulin (PH4) for Intravenous Injection Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales in Volume by Region (2017-2022) & (K Units)
    Table 29. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales in Volume Forecast by Region (2023-2028) & (K Units)
    Table 30. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales in Volume by Country (2017-2028) & (K Units)
    Table 33. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales in Volume by Region (2017-2028) & (K Units)
    Table 35. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales in Volume by Country (2017-2028) & (K Units)
    Table 37. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Sales in Volume by Country (2017-2028) & (K Units)
    Table 39. Latin Americaa Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales in Volume by Country (2017-2028) & (K Units)
    Table 41. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. Boya-Bio Corporation Information
    Table 43. Boya-Bio Description and Business Overview
    Table 44. Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 45. Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Product
    Table 46. Boya-Bio Recent Development
    Table 47. Beijing Tiantan Biological Products Corporation Information
    Table 48. Beijing Tiantan Biological Products Description and Business Overview
    Table 49. Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 50. Beijing Tiantan Biological Products Product
    Table 51. Beijing Tiantan Biological Products Recent Development
    Table 52. Guangdong Shuagnlin Bio-pharmacy Corporation Information
    Table 53. Guangdong Shuagnlin Bio-pharmacy Description and Business Overview
    Table 54. Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 55. Guangdong Shuagnlin Bio-pharmacy Product
    Table 56. Guangdong Shuagnlin Bio-pharmacy Recent Development
    Table 57. Weiguang Biological Corporation Information
    Table 58. Weiguang Biological Description and Business Overview
    Table 59. Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 60. Weiguang Biological Product
    Table 61. Weiguang Biological Recent Development
    Table 62. Hualan Bio Corporation Information
    Table 63. Hualan Bio Description and Business Overview
    Table 64. Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 65. Hualan Bio Product
    Table 66. Hualan Bio Recent Development
    Table 67. CTBB Corporation Information
    Table 68. CTBB Description and Business Overview
    Table 69. CTBB Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 70. CTBB Product
    Table 71. CTBB Recent Development
    Table 72. Sinopharm Corporation Information
    Table 73. Sinopharm Description and Business Overview
    Table 74. Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 75. Sinopharm Product
    Table 76. Sinopharm Recent Development
    Table 77. Nanyue Biopharming Corporation Information
    Table 78. Nanyue Biopharming Description and Business Overview
    Table 79. Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 80. Nanyue Biopharming Product
    Table 81. Nanyue Biopharming Recent Development
    Table 82. Shanghai RAAS Corporation Information
    Table 83. Shanghai RAAS Description and Business Overview
    Table 84. Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 85. Shanghai RAAS Product
    Table 86. Shanghai RAAS Recent Development
    Table 87. Key Raw Materials Lists
    Table 88. Raw Materials Key Suppliers Lists
    Table 89. Human Immumoglobulin (PH4) for Intravenous Injection Customers List
    Table 90. Human Immumoglobulin (PH4) for Intravenous Injection Distributors List
    Table 91. Research Programs/Design for This Report
    Table 92. Key Data Information from Secondary Sources
    Table 93. Key Data Information from Primary Sources
List of Figures
    Figure 1. Human Immumoglobulin (PH4) for Intravenous Injection Product Picture
    Figure 2. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Human Immumoglobulin (PH4) for Intravenous Injection Market Size 2017-2028 (US$ Million)
    Figure 4. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales 2017-2028 (K Units)
    Figure 5. United States Human Immumoglobulin (PH4) for Intravenous Injection Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States Human Immumoglobulin (PH4) for Intravenous Injection Market Size 2017-2028 (US$ Million)
    Figure 7. United States Human Immumoglobulin (PH4) for Intravenous Injection Sales 2017-2028 (K Units)
    Figure 8. United States Human Immumoglobulin (PH4) for Intravenous Injection Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States Human Immumoglobulin (PH4) for Intravenous Injection Market Share in Global, in Volume (K Units) 2017-2028
    Figure 10. Human Immumoglobulin (PH4) for Intravenous Injection Report Years Considered
    Figure 11. Product Picture of 1g/20ml
    Figure 12. Product Picture of 1.25g/25ml
    Figure 13. Product Picture of 2.5g/50ml
    Figure 14. Product Picture of 5g/100ml
    Figure 15. Product Picture of 10g/200ml
    Figure 16. Global Human Immumoglobulin (PH4) for Intravenous Injection Market Share by Type in 2022 & 2028
    Figure 17. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 18. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Type (2017-2028)
    Figure 19. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Type (2017-2028) & (K Units)
    Figure 20. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Type (2017-2028)
    Figure 21. Global Human Immumoglobulin (PH4) for Intravenous Injection Price by Type (2017-2028) & (US$/Unit)
    Figure 22. United States Human Immumoglobulin (PH4) for Intravenous Injection Market Share by Type in 2022 & 2028
    Figure 23. United States Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 24. United States Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Type (2017-2028)
    Figure 25. United States Human Immumoglobulin (PH4) for Intravenous Injection Sales by Type (2017-2028) & (K Units)
    Figure 26. United States Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Type (2017-2028)
    Figure 27. United States Human Immumoglobulin (PH4) for Intravenous Injection Price by Type (2017-2028) & (US$/Unit)
    Figure 28. Product Picture of Hospital
    Figure 29. Product Picture of Clinic
    Figure 30. Product Picture of Others
    Figure 31. Global Human Immumoglobulin (PH4) for Intravenous Injection Market Share by Application in 2022 & 2028
    Figure 32. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 33. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Application (2017-2028)
    Figure 34. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2017-2028) & (K Units)
    Figure 35. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Application (2017-2028)
    Figure 36. Global Human Immumoglobulin (PH4) for Intravenous Injection Price by Application (2017-2028) & (US$/Unit)
    Figure 37. United States Human Immumoglobulin (PH4) for Intravenous Injection Market Share by Application in 2022 & 2028
    Figure 38. United States Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 39. United States Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Application (2017-2028)
    Figure 40. United States Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2017-2028) & (K Units)
    Figure 41. United States Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Application (2017-2028)
    Figure 42. United States Human Immumoglobulin (PH4) for Intravenous Injection Price by Application (2017-2028) & (US$/Unit)
    Figure 43. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 44. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 45. U.S. Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Canada Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 48. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 49. Germany Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 50. France Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 51. U.K. Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Italy Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 53. Russia Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 55. Asia-Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 56. China Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 57. Japan Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 58. South Korea Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 59. India Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 60. Australia Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. Taiwan Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. Indonesia Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. Thailand Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 64. Malaysia Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 65. Philippines Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 66. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 67. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 68. Mexico Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 69. Brazil Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 70. Argentina Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 71. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 72. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 73. Turkey Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 74. Saudi Arabia Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 75. UAE Human Immumoglobulin (PH4) for Intravenous Injection Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 76. Human Immumoglobulin (PH4) for Intravenous Injection Value Chain
    Figure 77. Human Immumoglobulin (PH4) for Intravenous Injection Production Process
    Figure 78. Channels of Distribution
    Figure 79. Distributors Profiles
    Figure 80. Bottom-up and Top-down Approaches for This Report
    Figure 81. Data Triangulation
    Figure 82. Key Executives Interviewed